Share Price
~$30
snapshot March 2026
Market Cap
~$34B
NASDAQ | USD
Revenue 2025
$17.3B
+4.3% Y/Y | 5-year high
Net Income 2025
$1.41B
2024: ($1.64B) | EPS $1.23
Gross Margin 2025
51.8%
2022: 46.7% | consistent improvement
Net Debt
$13.3B
2024: $14.5B (-$1.2B)
1 Company Profile
Teva Pharmaceutical Industries is the world’s largest generic-drugs company, founded in 1901 in Jerusalem and today operating in more than 60 countries with headquarters in Tel Aviv. The company is dual-listed — traded on NASDAQ (TEVA) and on the Tel Aviv Stock Exchange, and is a constituent of the TA-35 index. Teva is regarded as one of the flagship stocks of the Israeli pharmaceutical sector, and although it is a global company with most of its activity in the US and Europe, it serves as a marker and benchmark for the Israeli biotech and pharma economy. The company combines a massive generic business — hundreds of products across 60+ countries — with a branded specialty portfolio led by Austedo and Ajovy, and a long-running turnaround strategy following the Copaxone patent cliff.
| מוצר | תחום | תפקיד אסטרטגי |
|---|
| AUSTEDO | Tardive Dyskinesia + Huntington | מנוע צמיחה מרכזי — פוטנציאל blockbuster |
| AJOVY | מיגרנה (CGRP) | תחרות גלובלית מול Aimovig, Emgality |
| UZEDY | סכיזופרניה (LAI) | מוצר חדש — זריקה ארוכת טווח |
| COPAXONE | טרשת נפוצה | מוצר legacy בירידה |
| פורטפוליו גנרי | מאות מוצרים | הבסיס הרחב — Scale advantage |
מקור: SEC 10-K FY2025
2 Key Financial Observations
This summary is not a recommendation. It is a factual list of key financial metrics.
Performance — 5 Years ($M)
| Year | הכנסות | רווח נקי | שולי גולמי |
|---|
| 2021 | 15,878 | 417 | 47.8% |
| 2022 | 14,925 | (2,446) | 46.7% |
| 2023 | 15,846 | (559) | 48.2% |
| 2024 | 16,544 | (1,639) | 48.7% |
| 2025 | 17,258 | 1,410 | 51.8% |
תזרים וחוב ($M)
| Metric | 2024 | 2025 |
|---|
| תזרים מפעילות | 1,247 | 1,649 |
| FCF | 749 | 1,148 |
| ריבית ששולמה | 1,004 | 950 |
| חוב כולל | 17,783 | 16,806 |
| חוב נטו | 14,483 | 13,250 |
| הון עצמי | 5,373 | 7,910 |
Missing data: Pipeline R&D detail, קצב פירעון מפורט Annual, פילוח גיאוגרפי של פשרות עתידיות.
רווח נקי GAAP — 5 שנים ($M)
שולי רווח גולמי — מגמה (%)
FCF מול ריבית ששולמה ($M)
תזרים מפעילות — מגמה ($M)
3 Industry & Competitive Context
פארמה גלובלית — שוק לא ציקלי, ביקוש יציב בכל מצב כלכלי. שוק הגנריקה תחרותי ומפוזר; שוק החדשנות (Innovative) ריכוזי יותר. רגולציית IRA אמריקאית ולחצי תמחור Medicare מהווים רוח נגדית; פקיעת פטנטים של תרופות ביולוגיות פותחת שוק ביוסימילרים גדל.
| מתחרה | תחום עיקרי | הבדל מטבע |
|---|
| Sandoz (Novartis spin-off) | גנריקה | המתחרה הישיר ביותר בגנריקה |
| Viatris | גנריקה + ברנדים | מיזוג Mylan-Upjohn |
| Sun Pharma | גנריקה הודית | עלות ייצור נמוכה |
| AbbVie | Innovative — CNS | מתחרה ב-AUSTEDO |
| Neurocrine Biosciences | INGREZZA | מתחרה ישירה ל-AUSTEDO |
4 Risk Factors
| Risk | Context |
|---|
| נטל החוב | $16.8B חוב כולל, ריבית של ~$950M Annualת. כל ירידה בריבית מהווה רוח גבית, וכל עלייה במרווחי האשראי מייקרת מחזור |
| מוניטין $16B (39% מנכסים) | טבע רשמה ירידות ערך מוניטין כבדות בעבר. רגישה ל-impairment חוזר אם הפעילות תיחלש |
| תלות מוצרית | חלק ניכר מהצמיחה תלוי ב-AUSTEDO. כניסת מתחרה גנרי לאחר פקיעת פטנט — סיכון מהותי |
| תביעות אופיואידים | טבע שילמה ~$467M ב-2025 ו-$761M ב-2024 בפשרות. רוב ההסדרים סגורים, אך תביעות חדשות אפשריות |
| שחיקת מחירים בגנריקה | לחץ מחירים מתמיד ממתחרים הודיים וסיניים. מאלץ מעבר לחדשנות |
| רגולציה אמריקאית | IRA + Medicare price negotiation — משפיעים על הכנסות מתרופות מובילות |
5 Analytical Lens — The Questions We Ask
In professional company analysis, the question is not "is this good?" but rather "through which lenses must this company be examined so that we do not miss what matters most?" At Bakshi Finance, every analysis passes through six lenses. הטקסט למטה — לא הערכה. הוא המיפוי של השאלות שהניתוח הזה אמור לענות עליהן.
This framework is intended to structure analysis, not to produce an investment conclusion.
Growth
Revenue grows at 4-6% since 2023, primarily from AUSTEDO. How much is mix-shift (innovation replacing generics) versus volume growth? What is the outlook once AUSTEDO loses patent protection? Can the biosimilars pipeline replace that revenue?
Profitability
Gross margin improved from 46.7% to 51.8% over three years. How much is structural (mix) vs temporary (cost savings after restructuring)? What is the ratio between GAAP profit (volatile) and Non-GAAP (~22.9% operating)?
Leverage
$16.8B debt, $950M annual interest, Debt/EBITDA ~3.4×. What is the maturity schedule? What percentage is fixed vs variable? How will Fed cuts in 2026-2027 affect refinancing costs?
Competitive Position
The world’s largest generic portfolio (60+ countries) = scale advantage. Is scale a real moat in a market where Indians and Chinese manufacture at lower cost? Where does AUSTEDO stand against INGREZZA?
Management Quality
Richard Francis has led a dramatic turnaround since 2023. How personal-dependent is the turnaround on him? What is the strategy after debt reduction completes — dividend reinstatement? Acquisitions? R&D investment?
Business Complexity / Risk
Teva operates across four segments, dozens of countries, varied regulations. Where would a simplistic analysis go wrong? How should one treat the $1.8B GAAP vs Non-GAAP gap? What are the implications of an accumulated deficit of $13.8B for future dividends?
6 Scenario Framework
Scenarios are descriptive, not predictive. They outline possible conditions, not expected outcomes.
These scenarios carry no probability assessment, no preferred direction, and no expectation regarding which, if any, will materialise.
Constructive Scenario — if the following conditions hold:
The profitability inflection seen in 2025 continues — gross margins hold above 50%, AUSTEDO continues toward $1B+ in revenue, new biosimilars enter the market, and the Fed reduces rates enabling lower-cost debt refinancing. Under these conditions, net debt continues to decline at $1B+ per year, FCF improves, and dividend reinstatement becomes possible in 2027-2028.
Base Scenario — if current trends continue:
Revenue grows 3-5% annually, gross margins stable around 50%, net debt falls at ~$1B per year, rates remain stable. One-off expenses (settlements, restructuring) continue but diminish. Free cash flow stabilises at $1.0-1.3B annually.
Adverse Scenario — if the following risks materialise:
Additional goodwill impairment (>$1B) pressures equity, new opioid claims at meaningful scale, AUSTEDO encounters patent challenges or earlier competition than expected, or renewed rate increases raise refinancing costs. Under these conditions, FCF erodes and debt reduction slows.
Scenarios describe conditions, not forecasts. There is no preferred direction and no probability assessment expressed in this framework.
7 How to Think About This Company
Teva is not a typical pharmaceutical company — it is a turnaround story that is not yet complete. Since 2017, the company has been recovering from the failed Actavis acquisition (2016, $40B) which created a historic debt load. Over seven years the company reported losses, cumulative goodwill impairments exceeding $4B, and opioid settlements in the billions. 2025 was a genuine inflection — the first GAAP profit since 2021, gross margin at an all-time high of 51.8%, and net debt down $1.2B. The real question in analysing Teva is not "is the turnaround real" (it is), but rather "is it sustainable without the one-off sales and temporary cost tailwinds?"
The critical variables to monitor are three. First, the AUSTEDO trajectory — the product drives most of the medium-term growth story. The question is not just whether it continues growing, but how much of the growth is market expansion (new patients) versus market-share capture (from INGREZZA). Second, the debt-reduction path — net debt fell from $14.5B to $13.3B in 2025, which is excellent; but $13.3B is still an enormous burden. The question is pace — whether the company can reach below $10B by 2028. Third, the GAAP–Non-GAAP gap. The ~$1.8B gap in 2025 is a material decline from $2.5B+ in prior years, but it is still material. Closing that gap is a meaningful part of what will define 2026-2027 true earnings.
Where the analysis may go wrong. First error — treating GAAP profit of $1.41B as "normal". This is an inflection-year profit, helped by a positive working-capital swing, lower settlement expense, and one-time AUSTEDO revenue upside. The question is the reasonable run-rate for 2026-2027 — likely lower. Second error — assessing debt without assessing interest. $16.8B of gross debt is a scary number; but $950M of annual interest is what affects FCF day to day. The right measure for this company is Interest Coverage (4.2× Non-GAAP), not debt/EBITDA alone. Third error — treating $16B of goodwill as "an asset". In reality, it is a residual of the Actavis acquisition that has already been impaired by $4B+. Any stress on operations could trigger another impairment test.
What distinguishes professional analysis of Teva from headlines. Headlines on Teva speak of "turnaround" or of "heavy debt". Professional analysis addresses three things: (a) what distinguishes one-off expenses that should decline from recurring ones (opioid settlements ending, restructuring yes, but R&D continues); (b) FCF sensitivity to interest cost — every 1% decline in credit spread = $150M+ of additional FCF per year; (c) the post-AUSTEDO scenario. These are not what one buys or sells — they are what one asks before deciding.
The difference between surface-level analysis and professional thinking often lies in the variables that are not immediately visible.
The difference between surface-level analysis and professional thinking often lies in the variables that are not immediately visible.
8 Sources & Data
| # | Source | Date | Type |
|---|
| 1 | SEC EDGAR — Form 10-K FY2025 (P1720750-00) | March 2026 | Official — SEC |
| 2 | SEC EDGAR — Form 10-K FY2023 (P1574153-00) | מרץ 2024 | Official — SEC |
| 3 | tevapharm.com — IR | Quarterly | Official — company website |
| 4 | maya.tase.co.il — פרטי חברה (טבע) | April 2026 | Official — Stock Exchange |
| 5 | NASDAQ.com — TEVA quote | April 2026 | Official — Stock Exchange |
| 6 | stockanalysis.com — מכפילים | April 2026 | Secondary |
Missing: Pipeline R&D detail, קצב פירעון מפורט Annual, פילוח גיאוגרפי של פשרות עתידיות.
